Aclarubicin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Aclarubicin
Aclarubicin.svg
Clinical data
AHFS/Drugs.com International Drug Names
Routes of
administration
IV
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
ECHA InfoCard 100.055.277
Chemical and physical data
Formula C42H53NO15
Molar mass 811.86 g/mol
3D model (Jmol)
Melting point 151 to 153 °C (304 to 307 °F) (decomposes)
 NYesY (what is this?)  (verify)

Aclarubicin (INN) or aclacinomycin A[1] is an anthracycline drug[2] that is used in the treatment of cancer. Soil bacteria Streptomyces galilaeus can produce aclarubicin. It can induce histone eviction from chromatin upon intercalation.[3][4]

References[edit]

  1. ^ CID 451415 from PubChem
  2. ^ Jensen PB, Jensen PS, Demant EJ, et al. (October 1991). "Antagonistic effect of aclarubicin on daunorubicin-induced cytotoxicity in human small cell lung cancer cells: relationship to DNA integrity and topoisomerase II". Cancer Res. 51 (19): 5093–9. PMID 1655244. 
  3. ^ Pang B, Qiao X, Janssen L, Velds A, Groothuis T, Kerkhoven R, Nieuwland M, Ovaa H, Rottenberg S, van Tellingen O, Janssen J, Huijgens P, Zwart W, Neefjes J (2013). "Drug-induced histone eviction from open chromatin contributes to the chemotherapeutic effects of doxorubicin". Nature Communications. 4: 1908. PMC 3674280Freely accessible. PMID 23715267. doi:10.1038/ncomms2921. 
  4. ^ Pang B, de Jong J, Qiao X, Wessels LF, Neefjes J (2015). "Chemical profiling of the genome with anti-cancer drugs defines target specificities". Nature Chemical Biology. 11 (7): 472. PMID 25961671. doi:10.1038/nchembio.1811.